dipeptidyl
wide
express
enzym
transduc
action
anchor
transmembran
molecul
solubl
circul
protein
membraneassoci
solubl
exert
catalyt
activ
cleav
protein
contain
posit
alanin
prolin
enzymat
cleavag
altern
inactiv
peptid
gener
new
bioactiv
moieti
may
exert
compet
novel
activ
widespread
use
select
inhibitor
treatment
type
diabet
heighten
interest
molecular
mechan
inhibitor
exert
pleiotrop
action
review
biolog
focu
identif
pharmacolog
vs
physiolog
substrat
elucid
mechan
action
studi
employ
genet
elimin
chemic
reduct
activ
review
data
identifi
role
key
substrat
transduc
glucoregulatori
antiinflammatori
cardiometabol
action
inhibitor
preclin
clinic
studi
final
highlight
experiment
pitfal
technic
challeng
encount
studi
design
understand
mechan
action
downstream
target
activ
inhibit
ipeptidyl
multifunct
protein
exert
biolog
activ
pleiotrop
action
includ
proteas
activ
associ
adenosin
deaminas
ada
interact
extracellular
matrix
cell
surfac
coreceptor
activ
mediat
viral
entri
regul
intracellular
signal
transduct
coupl
control
cell
migrat
prolifer
complex
action
amplifi
panopli
bioactiv
substrat
turn
act
eleg
biochem
messeng
multipl
tissu
includ
immun
neuroendocrin
system
biolog
interest
enzym
heighten
approv
highli
select
inhibitor
treatment
type
diabet
sever
excel
review
highlight
result
clinic
trial
use
inhibitor
treat
type
diabet
other
compar
structur
pharmacokinet
differ
compar
efficaci
uniqu
inhibitor
summar
cardiovascular
renal
safeti
data
surround
use
inhibitor
review
approach
literatur
differ
perspect
highlight
biolog
enzym
critic
assess
experi
report
identif
role
substrat
emphas
studi
identifi
substrat
turn
assess
knowledg
inhibitor
act
substrat
transduc
pleiotrop
action
preclin
clinic
studi
given
clinic
relev
biolog
treatment
diabet
focu
attent
mechan
action
relev
pathophysiolog
treatment
diabet
complic
reader
interest
review
summar
clinic
trial
data
encourag
consult
sever
excel
recent
summari
discoveri
genom
organ
superfamili
relat
enzym
discov
new
aminopeptidas
uniqu
substrat
characterist
later
determin
ident
tcell
activ
antigen
cluster
differenti
cd
rat
liver
membran
glycoprotein
mous
thymocyteactiv
molecul
human
gene
identifi
locat
long
arm
chromosom
compris
exon
encod
acid
protein
classic
serin
proteas
catalyt
site
encod
two
exon
exon
respect
mous
found
chromosom
interestingli
exon
exon
present
singl
exon
wide
express
numer
tissu
includ
endotheli
cell
multipl
vascular
bed
render
enzym
highli
access
peptid
substrat
circul
gut
liver
lung
kidney
human
gene
encod
two
predomin
mrna
transcript
larger
mrna
whose
distribut
widespread
transcript
restrict
placenta
kidney
lung
liver
furthermor
multipl
minor
splice
variant
gene
describ
howev
function
signific
variou
mrna
transcript
may
contain
differ
sequenc
poli
tail
translat
classic
bioactiv
protein
remain
unclear
member
serin
peptidaseprolyl
oligopeptidas
gene
famili
often
subclassifi
partli
structur
function
includ
membranebound
peptidas
fibroblast
activ
protein
fap
sepras
resid
cytoplasm
enzym
nonenzymat
member
present
neuron
membran
prolyl
endopeptidas
posit
ident
residu
essenti
catalyt
activ
within
ctermin
region
relat
enzym
highli
conserv
prokaryot
eukaryot
despit
signific
differ
sequenc
enzymat
complex
engend
function
relat
dash
dipeptidyl
peptidas
activ
andor
structur
homolog
enzym
replic
enzymat
activ
despit
differ
structur
local
thu
explain
activ
persist
genet
delet
pharmacolog
inhibit
transmit
signal
across
cell
membran
interact
membran
protein
figur
remark
protein
extracellular
includ
ctermin
catalyt
domain
cysteinerich
area
larg
glycosyl
region
link
flexibl
stalk
transmembran
segment
six
ntermin
amino
acid
predict
extend
cytoplasm
activ
site
ser
flank
classic
serin
peptidas
motif
chemic
crosslink
experi
perform
cell
nativ
gel
analysi
isol
semin
fluid
demonstr
dimer
predomin
speci
studi
analyz
recombin
produc
baculoviralinfect
insect
cell
demonstr
exhibit
much
smaller
amount
enzymat
activ
monomer
form
activ
significantli
increas
upon
homodimer
mutat
studi
demonstr
ctermin
loop
essenti
dimer
format
optim
catalyt
efficaci
analysi
protein
crystal
structur
demonstr
also
form
tetram
two
solubl
protein
two
membranebound
protein
may
affect
effici
entri
cleavag
substrat
catalyt
activ
site
allow
cellcel
commun
studi
cell
coexpress
demonstr
format
heteromer
complex
enzym
retain
proteas
activ
membranebound
initi
intracellular
signal
interact
ada
caspas
recruit
domain
contain
protein
tcell
antigen
prospect
bind
partner
includ
receptor
exchang
thromboxan
receptor
although
specif
interact
site
identifi
also
bind
extracellular
matrix
compon
collagen
fibronectin
bind
protein
ada
mediat
amino
acid
residu
independ
substrat
bind
site
figur
catalyt
activ
liber
plasma
membran
produc
solubl
circul
form
aa
lack
intracellular
tail
transmembran
region
account
substanti
proport
activ
human
serum
figur
solubl
form
first
identifi
serum
saliva
detect
cerebrospin
semin
fluid
bile
also
activ
intracellular
signal
pathway
increas
prolifer
human
lymphocyt
independ
either
catalyt
activ
bind
ada
impair
insulinmedi
activ
akt
human
adipocyt
skelet
muscl
smooth
muscl
cell
vitro
remark
action
attribut
regul
tcell
migrat
upregul
costimulatori
molecul
requir
function
catalyt
catalyt
activ
mechan
activ
signal
transduct
possibl
interact
mannos
receptor
via
molecular
interact
poorli
understood
activ
subject
regul
mani
level
includ
control
gene
protein
express
interact
bind
partner
modul
enzym
activ
gene
contain
convent
tataa
ccaat
promot
sequenc
character
cytosineguaninerich
promot
region
human
gene
promot
contain
consensu
site
transcript
factor
key
role
metabol
includ
specif
protein
activ
protein
egfrspecif
transcript
factor
hepatocyt
nuclear
nuclear
factorb
import
cytokin
activ
demonstr
chronic
b
lymphocyt
leukemia
cell
interferon
stimul
bind
ga
interferon
sequenc
consensu
sequenc
promot
gene
lead
upregul
intracellular
cellsurfac
express
well
activ
cellsurfac
intracellular
express
also
highli
regul
often
low
basal
condit
induc
markedli
exampl
upon
tcell
activ
mitogen
antigen
stimuli
phytohaemagglutininactiv
cultur
human
peripher
blood
mononuclear
cell
immunofluoresc
analysi
determin
significantli
upregul
respons
key
factor
differenti
naiv
cell
cell
data
togeth
evid
studi
suggest
import
role
activ
immun
cell
control
shed
increas
level
circul
form
figur
poorli
understood
human
adipocyt
isol
viscer
depot
inflammatori
stimuli
insulin
increas
releas
despit
lack
chang
mrna
express
analysi
mrna
express
viscer
adipos
obes
human
subject
demonstr
rel
increas
mrna
transcript
enhanc
releas
cultur
adipocyt
ex
vivo
nevertheless
wherea
mani
studi
measur
associ
level
differ
diseas
state
littl
insight
provid
mechan
regul
shed
biolog
activ
condit
studi
dark
agouti
rat
demonstr
kidney
extract
exhibit
highest
activ
kinet
assay
glypropna
substrat
present
per
gram
wet
weight
organ
test
high
activ
also
found
spleen
lung
thymu
liver
wherea
medium
level
activ
found
intestin
aorta
bone
marrow
interestingli
plasma
activ
reduc
kidney
transplant
congen
dark
agouti
donor
rat
wildtyp
recipi
rat
suggest
kidney
import
sourc
studi
congen
dark
agouti
donor
rat
lethal
irradi
receiv
transfer
wildtyp
bone
marrow
demonstr
week
surgeri
bone
marrow
sourc
activ
plasma
howev
marrowderiv
cell
type
respons
determin
studi
highlight
limit
understand
cell
type
tissu
contribut
gener
plasma
activ
vivo
contain
eight
potenti
nglycosyl
site
contribut
fold
stabil
although
glycosyl
may
contribut
approxim
total
molecular
weight
mutat
analysi
determin
glycosyl
site
requir
dimer
catalyt
activ
ada
bind
howev
ntermin
sialyl
facilit
traffick
apic
membran
interestingli
molecular
analysi
isoform
isol
rat
kidney
brush
border
membran
reveal
extens
heterogen
oligosaccharid
singl
studi
sialyl
isoform
peripher
blood
mononuclear
cell
hivinfect
subject
correl
extent
sialyl
increas
patient
age
interact
propos
alter
ionic
charg
antigen
highli
sialyl
readili
inhibit
cation
peptid
desialyl
vibrio
cholera
neuraminidas
increas
activ
henc
extent
sialyl
may
repres
anoth
mechan
control
activ
first
investig
role
hydrolysi
dietari
prolyl
peptid
subsequ
studi
use
isol
use
immunoaffin
chromatographi
ada
bind
identifi
primari
enzym
respons
gener
glypropnitroanilid
substrat
human
serum
known
cleav
dozen
peptid
includ
chemokin
neuropeptid
regulatori
peptid
contain
prolin
alanin
residu
posit
aminotermin
region
despit
prefer
posit
prolin
altern
residu
hydroxyprolin
dehydroprolin
alanin
glycin
threonin
valin
leucin
penultim
posit
also
cleav
suggest
requir
stereochemistri
cleavag
postprolin
peptid
bond
inactiv
peptid
andor
gener
new
bioactiv
peptid
see
figur
therebi
regul
divers
biolog
process
multipl
experiment
approach
employ
identif
character
substrat
figur
commonli
put
substrat
incub
plasma
contain
cell
express
endogen
transfect
purifi
peptid
cleavag
determin
use
one
analyt
techniqu
kinet
paramet
mani
substrat
determin
use
vitro
enzym
assay
approach
allow
use
suffici
quantiti
peptid
substrat
enabl
detect
intact
vs
cleav
substrat
vitro
extens
substrat
identif
anim
human
vivo
much
challeng
substrat
neuropeptid
chemokin
regulatori
peptid
circul
low
concentr
experiment
strategi
infer
biolog
import
peptid
cleavag
includ
infus
put
substrat
mous
rat
inactiv
mutat
gene
coadministr
peptid
substrat
inhibitor
normal
anim
human
figur
approach
yield
interest
data
reveal
import
potenti
pharmacolog
action
exogen
substrat
whether
also
control
circul
intact
vs
cleav
physiolog
level
endogen
substrat
vivo
less
clear
requir
analysi
level
intact
vs
cleav
peptid
anim
inactiv
mutat
gene
anim
human
treat
inhibitor
figur
challeng
identif
endogen
physiolog
substrat
cleav
tabl
peptid
whose
rel
level
intact
vs
cleav
isoform
significantli
differ
inhibit
vivo
gener
requir
highli
sensit
regionspecif
immunoassay
andor
analyt
techniqu
combin
immunopurif
peptid
identif
mass
spectrometri
challeng
understand
biolog
may
includ
inabl
demonstr
chang
level
intact
vs
cleav
peptid
vivo
due
technic
limit
assay
sensit
furthermor
may
similarli
difficult
ascertain
physiolog
pharmacolog
relev
chang
peptid
biolog
genet
elimin
pharmacolog
reduct
activ
due
absenc
select
peptid
antagonist
mous
knockout
model
peptid
receptor
interest
altern
experiment
approach
defin
import
substrat
includ
precis
replac
circul
level
cleav
substrat
maintain
inhibit
use
peptid
reproduc
physiolog
level
nativ
peptid
design
substrat
cleav
exclus
recombin
cellassoci
plasma
vitro
whose
biolog
alter
pharmacolog
infus
vivo
pharmacolog
substrat
tabl
figur
given
technic
challeng
quantif
character
low
level
intact
vs
cleav
substrat
seem
like
pharmacolog
substrat
shown
tabl
may
ultim
reclassifi
physiolog
substrat
pend
advanc
sensit
analyt
techniqu
wherev
possibl
distinguish
pharmacolog
vs
physiolog
substrat
provid
overview
commonli
studi
substrat
potenti
signific
pathophysiolog
endocrin
metabol
disord
although
activ
may
broadli
regul
physiolog
numer
signal
system
impact
numer
ou
organ
diseas
focu
discuss
substrat
relev
metabol
relat
neuroendocrin
system
tabl
activ
control
immun
cell
activ
subclin
overt
inflamm
acceler
progress
diabet
obes
also
discuss
select
data
link
regul
chemokin
biolog
activ
highlight
subset
substrat
evalu
evid
identif
physiolog
peptid
substrat
ie
intact
peptid
cleavag
product
detect
differ
level
wildtyp
vs
knockout
anim
anim
human
subject
treat
select
inhibitor
pharmacolog
substrat
ie
vitro
truncat
observ
penultim
residu
predominantli
vitro
bnp
synthes
acid
precursor
preprobnp
process
probnp
subsequ
cleav
furin
corin
bnp
promot
natriuresi
engag
vitro
bnp
bnp
bnp
detect
plasma
patient
heart
failur
bnp
bnp
stimul
product
cgmp
howev
natriuret
diuret
vasodilatori
activ
bnp
reduc
rel
bnp
vivo
sitagliptin
potenti
recoveri
cardiac
function
infus
bnp
pig
pacinginduc
heart
failur
howev
littl
inform
chang
bnp
vs
bnp
anim
human
treat
inhibitor
erythropoietin
acid
protein
posit
prolin
cleav
vitro
vivo
subcutan
administr
erythropoietin
null
mice
augment
reticulocyt
releas
blood
wherea
inject
protein
led
diminish
reticul
respons
inhibit
respons
fulllength
erythropoietin
suggest
cleav
erythropoietin
may
act
competit
inhibitor
hematopoiesi
respons
radiat
chemotherapi
augment
genet
pharmacolog
reduct
activ
mice
howev
less
clear
whether
inhibit
augment
erythropoietindepend
hematopoiesi
human
avail
data
suggest
erythropoietin
may
physiolog
substrat
howev
rigor
biochem
quantif
intact
vs
cleav
erythropoietin
anim
human
reduc
activ
requir
chemokin
eotaxin
small
peptid
chemoattract
properti
contain
one
cystein
residu
n
terminu
cc
chemokin
contain
four
consecut
conserv
cystein
residu
wherea
cxl
chemokin
display
four
cystein
two
tandem
cystein
residu
separ
singl
amino
acid
eotaxin
cc
motif
chemokin
ccl
acid
chemokin
secret
cell
attract
eosinophil
cleav
eotaxin
reduc
potenc
eosinophil
chemotaxi
howev
eotaxin
retain
antihiv
activ
cc
chemokin
receptor
cell
exhibit
eotaxin
henc
cleavag
select
dampen
eotaxinmedi
immun
respons
without
modul
eotaxindepend
viral
entri
grp
acid
peptid
member
bombesin
famili
wide
express
neuroendocrin
system
includ
parasympathet
neuron
pancrea
gut
brain
cleavag
grp
produc
grp
grp
administr
inhibitor
valinepyrrolidid
gavag
infus
grp
led
increas
acut
insulin
respons
iv
glucos
anesthet
mice
howev
grp
also
stimul
secret
may
contribut
indirect
stimul
insulin
secret
would
augment
presenc
inhibitor
although
grp
isol
canin
intestin
brain
biolog
import
unknown
furthermor
whether
modul
activ
control
biolog
endogen
grp
vivo
unclear
glucagon
acid
hormon
secret
pancreat
stimul
hepat
glucos
product
diabet
character
lack
suppress
glucagon
postprandi
state
contribut
aberr
metabol
glucos
lipid
mass
spectrometri
analysi
demonstr
incub
purifi
porcin
glucagon
vitro
result
format
glucagon
glucagon
human
serum
glucagon
metabol
glucagon
ex
vivo
inhibitor
ilethiazolidid
prevent
format
cleavag
product
vitro
nevertheless
degrad
glucagon
porcin
plasma
affect
inhibit
valinepyrrolidid
glucagon
degrad
modul
anesthet
pig
treat
inhibitor
furthermor
physiolog
therapeut
signific
enzymat
cleavag
unclear
inhibitor
univers
decreas
level
intact
glucagon
rodent
human
via
potenti
action
circul
level
glucagon
glucagon
report
anim
human
treat
inhibitor
collect
avail
data
consist
possibl
glucagon
pharmacolog
physiolog
substrat
secret
l
cell
found
mainli
distal
portion
intestin
tract
posttransl
cleavag
proglucagon
prohormon
convertas
pc
activ
circul
nh
peptid
cleav
gener
nh
respect
intact
enhanc
glucosestimul
insulin
secret
suppress
glucagon
secret
appetit
gastric
empti
action
mediat
singl
receptor
cleavag
elimin
classic
glucoregulatori
action
gener
peptid
less
receptor
affin
demonstr
ntermin
residu
requir
engag
plasma
level
intact
activ
increas
mice
rat
reduc
activ
anim
human
treat
inhibitor
henc
physiolog
substrat
although
amid
weak
antagonist
physiolog
relev
remain
unclear
pharmacolog
administr
achiev
level
higher
circul
physiolog
result
enhanc
glucos
clearanc
meal
ingest
independ
chang
insulin
glucagon
gastric
empti
pharmacolog
infus
also
reduc
hepat
glucos
product
obes
normalweight
human
subject
incomplet
defin
mechan
nevertheless
inhibit
result
mark
reduct
circul
littl
data
exist
surround
biolog
implic
reduc
low
undetect
level
vivo
henc
although
pharmacolog
administr
enhanc
glucos
clearanc
reduc
hepat
glucos
product
decreas
oxid
stress
blood
vessel
cardiomyocyt
biolog
relev
lower
level
context
inhibit
demonstr
acid
peptid
intestinotroph
activ
cosecret
enteroendocrin
l
cell
distal
bowel
cleavag
product
detect
hplc
rat
ileal
extract
human
plasma
inhibitor
valpyr
complet
abolish
format
human
plasma
vitro
exert
weak
agon
antagon
rodent
human
receptor
vitro
rodent
vivo
nevertheless
whether
inhibitormedi
reduct
vivo
physiolog
consequ
remain
unclear
nativ
potent
stimul
small
bowel
sb
growth
mice
howev
crypt
plu
villu
height
sb
mass
increas
rat
treat
nativ
contrast
equimolar
dose
nativ
potent
increas
sb
mass
mutant
rat
illustr
import
endogen
inactiv
rodent
furthermor
analog
exert
potent
intestinotroph
effect
rodent
human
plasma
level
intact
bioactiv
increas
treatment
anim
inhibitor
henc
physiolog
substrat
although
inhibitor
potenti
intestinotroph
action
coadminist
nativ
administr
inhibitor
alon
littl
consequ
intestin
action
nativ
endogen
vivo
gip
acid
peptid
deriv
preprogip
via
posttransl
process
mainli
within
k
cell
duodenum
proxim
jejunum
gip
also
express
islet
process
liber
gip
like
gip
stimul
insulin
secret
cleav
gip
releas
dipeptid
tyrala
gip
unabl
activ
gip
receptor
pharmacolog
level
function
weak
antagonist
vitro
nevertheless
whether
gip
function
physiolog
relev
antagonist
vivo
uncertain
gip
physiolog
substrat
plasma
level
intact
gip
increas
anim
human
administr
inhibitor
level
intact
gip
increas
mice
gcsf
acid
chemokin
stimul
bone
marrow
produc
hematopoiet
stem
cell
identifi
target
substrat
cleavag
reduc
chemotax
potenc
vitro
mice
whether
intact
vs
cleav
form
gcsf
significantli
differ
administr
inhibitor
unclear
gmcsf
acid
chemokin
secret
immun
cell
induc
hematopoiesi
inhibit
enhanc
colonystimul
activ
gmcsf
ex
vivo
vivo
interestingli
cleavag
product
gmcsf
bind
gmcsf
receptor
greater
affin
nativ
gmcsf
despit
lower
concentr
allow
truncat
gmcsf
competit
inhibit
signal
fulllength
gcsf
ghrh
produc
arcuat
nucleu
hypothalamu
bind
receptor
anterior
pituitari
stimul
releas
gh
turn
gh
stimul
hepat
releas
ghrh
among
first
peptid
identifi
substrat
rapidli
degrad
rodent
human
plasma
ghrh
ghrh
cleavag
block
upon
incub
human
plasma
inhibitor
diprotin
ghrh
exhibit
short
halflif
min
cleavag
initi
perceiv
critic
regul
ghrh
bioactiv
turn
axi
downstream
effector
ghrh
gh
acid
protein
produc
mainli
liver
identifi
pharmacolog
substrat
matrixassist
laser
desorptionionizationtim
flight
analysi
molecular
form
gener
incub
purifi
baculovirusinfect
insect
cell
howev
studi
pig
treat
sitagliptin
dose
inhibit
activ
fail
demonstr
increas
activ
intact
clinic
treatment
healthi
human
male
subject
sitagliptin
mg
day
produc
increas
concentr
serum
igfbind
protein
measur
elisa
furthermor
mice
rat
exhibit
increas
organ
growth
bodi
size
henc
avail
data
suggest
although
cleav
inactiv
ghrh
enzymat
inactiv
major
mechan
regul
bioactiv
axi
acid
nuclear
protein
regul
gene
transcript
may
releas
cell
necrosi
respons
tissu
damag
activ
secret
inflamm
pharmacolog
stimul
mobil
endotheli
cell
progenitor
enhanc
angiogenesi
wound
heal
immunoblot
protein
plasma
two
diabet
patient
treat
inhibitor
use
nterminalspecif
antisera
suggest
level
intact
may
increas
presenc
inhibitor
howev
remain
unclear
whether
cleavag
regul
biolog
activ
vivo
mdc
acid
protein
produc
macrophag
dendrit
cell
immun
respons
cleavag
recombin
mdc
vitro
result
small
amount
mdc
larg
mdc
interestingli
wherea
cleav
form
mdc
exhibit
reduc
chemotact
abil
isol
human
peripher
blood
monocyt
remain
respons
cleav
peptid
truncat
mdc
retain
abil
resist
hiv
infect
peripher
blood
mononuclear
cell
whether
modul
activ
similarli
regul
biolog
mdc
isoform
vivo
requir
analysi
acid
protein
chemoattract
properti
mononuclear
cell
cleav
vitro
gener
human
peripher
blood
mononuclear
cell
treat
exhibit
greater
chemotaxi
increas
ca
signal
compar
respons
although
cleavag
gener
enhanc
chemotaxi
vitro
whether
reduct
modul
proport
intact
vs
cleav
vivo
less
clear
oxyntomodulin
acid
proglucagonderiv
peptid
secret
l
cell
contain
acid
glucagon
sequenc
addit
eight
amino
acid
extens
c
terminu
uniqu
receptor
oxyntomodulin
identifi
howev
oxyntomodulin
activ
glucagon
receptor
solubl
recombin
human
cleav
oxyntomodulin
vitro
first
amino
acid
ntermin
sequenc
oxyntomodulin
ident
glucagon
note
pharmacolog
substrat
appear
undergo
meaning
cleavag
vivo
furthermor
lack
oxyntomodulinspecif
antagonist
receptor
challeng
elucid
import
oxyntomodulin
physiolog
target
commerci
avail
assay
reliabl
distinguish
intact
form
oxyntomodulin
pacap
acid
neuropeptid
exhibit
numer
action
endocrin
system
releas
local
islet
upon
stimul
parasympathet
nerv
pancrea
pacap
cleav
vitro
ctermin
variant
pacap
also
weakli
cleav
pacap
signal
famili
structur
relat
vasoact
intestin
peptid
pituitari
adenyl
cyclas
activ
pepdit
vpac
receptor
local
situ
hybrid
islet
pacap
direct
regul
insulin
secret
concentr
low
moll
place
among
potent
insulinotrop
peptid
describ
presenc
multipl
pacap
isoform
well
famili
relat
receptor
also
recogn
vasoact
intestin
peptid
vip
render
gener
pacapspecif
antagonist
highli
challeng
although
mice
exhibit
complex
metabol
phenotyp
display
signific
glucos
intoler
defect
insulin
secret
oral
iv
glucos
impair
insulinotrop
respons
pacap
vip
consist
import
endogen
pacap
control
insulin
secret
circul
level
pacap
remain
elev
iv
administr
mice
markedli
reduc
gener
pacap
similarli
inhibitor
valinepyrrolidid
potenti
insulinotrop
action
coadminist
synthet
ovin
pacap
mice
howev
whether
circul
local
concentr
endogen
pacap
increas
presenc
inhibitor
alter
mice
remain
unclear
difficult
ascertain
due
low
concentr
pacap
isoform
vivo
npi
acid
peptid
produc
hypothalamu
secret
cerebr
spinal
fluid
npi
also
local
human
adipos
tissu
sympathet
nerv
termini
associ
pancreat
blood
vessel
subset
develop
pancrea
cell
adapt
metabol
stress
npi
relat
peptid
peptid
yy
pancreat
polypeptid
exert
biolog
action
famili
structur
relat
receptor
cleavag
nativ
npi
gener
npi
strong
affin
receptor
consider
data
demonstr
cleavag
npi
vitro
modul
npi
receptor
select
figur
nevertheless
enzymat
cleavag
npi
complex
least
five
peptidas
identifi
cleav
npi
vitro
although
plasma
immunoreact
npi
level
elev
mice
experiment
coliti
analys
distinguish
intact
cleav
form
npi
furthermor
littl
data
assess
whether
envis
chang
level
endogen
npi
vs
npi
circul
andor
tissu
inhibit
account
compon
relev
biolog
effect
observ
inhibit
vivo
pyy
acid
peptid
secret
intestin
l
cell
respons
nutrient
ingest
cleavag
pyy
vitro
yield
pyy
select
agonist
figur
intact
pyy
intact
form
peptid
signal
cleavag
npi
pyy
gener
preferenti
signal
b
cleav
sp
signal
receptor
gener
sp
signal
pyy
healthi
human
subject
inhibit
energi
intak
convers
infus
pyy
inhibit
food
intak
wildtyp
fischer
rat
inactiv
point
mutat
gene
furthermor
circul
level
pyy
significantli
reduc
wherea
level
pyy
increas
diabet
human
subject
treat
sitagliptin
henc
pyy
physiolog
substrat
vivo
rant
acid
chemokin
secret
cell
fibroblast
interact
receptor
ntermin
truncat
produc
rant
retain
chemotact
properti
lymphocyt
longer
stimul
migrat
monocyt
eosinophil
rant
cleav
rant
continu
signal
receptor
vitro
rant
effect
rant
inhibit
viral
infect
mononuclear
cell
vitro
complex
potenti
rant
activ
underscor
observ
still
potenti
abil
rant
activ
cell
vitro
suggest
enzymeindepend
cooper
chemokin
activ
although
cleavag
rant
produc
potent
biolog
action
vitro
much
less
known
depend
rant
biolog
vivo
two
differ
isoform
also
known
cxc
motif
chemokin
describ
matur
protein
amino
acid
four
addit
ctermin
residu
henc
amino
acid
deriv
singl
gene
altern
rna
splice
wide
express
numer
cell
type
express
secret
often
induc
concomit
cellular
injuri
isoform
cleav
solubl
cellular
inactiv
antivir
chemotact
properti
cellbas
assay
vitro
activ
enhanc
migrat
hematopoiet
endotheli
progenitor
cell
site
ischem
injuri
inhibitor
employ
enhanc
tissu
heal
commonli
set
myocardi
vascular
ischemia
importantli
inhibit
reduc
ntermin
degrad
potenti
action
vivo
enabl
enhanc
activ
receptor
greater
stem
cell
mobil
site
injuri
case
mani
low
abund
substrat
quantif
level
intact
vs
vivo
challeng
due
lack
sensit
assay
discrimin
use
assay
employ
first
step
antibodybas
immunoenrich
follow
quantif
peptid
isoform
use
mass
spectrometri
wang
et
al
detect
increas
plasma
level
decreas
level
mice
acut
treat
inhibitor
furthermor
rel
increas
circul
level
intact
detect
plasma
rhesu
monkey
acut
treat
prolong
dose
inhibit
markedli
reduc
circul
level
similarli
assay
employ
antibodi
captur
follow
mass
spectrometri
detect
mark
reduct
plasma
mice
taken
togeth
avail
data
demonstr
physiolog
substrat
sp
tachykinin
acid
neurotransmitt
signal
predominantli
receptor
plasma
wildtyp
fischer
rat
cleav
recombin
sp
gener
sp
sp
via
mechan
sensit
inhibitor
diprotin
mice
exhibit
approxim
higher
level
circul
sp
implic
essenti
biolog
role
control
sp
biolog
although
potenti
sp
activ
postul
underli
pathophysiolog
nasopharyng
neurogen
inflamm
occasion
report
use
inhibitor
sp
also
rapidli
cleav
angiotensinconvert
enzym
neutral
endopeptidas
level
intact
vs
cleav
sp
low
difficult
quantifi
vivo
furthermor
extent
cutan
inflamm
induc
exogen
intraderm
administr
sp
human
subject
modifi
coadministr
sitagliptin
although
pharmacolog
infus
sp
potenti
vascular
releas
norepinephrin
increas
heart
rate
human
studi
current
firm
clinic
evid
inhibit
potenti
cardiovascular
activ
endogen
sp
human
subject
henc
biolog
import
sp
put
endogen
physiolog
substrat
requir
scrutini
initi
character
modul
tcell
activ
prolifer
observ
level
activ
elev
cell
patient
autoimmun
disord
inflammatori
condit
includ
rheumatoid
arthriti
led
evalu
inhibitor
treatment
immun
disord
involv
aberr
tcell
function
howev
interpret
studi
complic
observ
catalyt
activ
requir
mediat
effect
tcell
function
express
upregul
mani
cancer
associ
extracellular
matrix
protein
consequ
inhibit
evalu
tcell
malign
solid
tumor
metastas
nonselect
inhibitor
fap
valboropro
talabostat
studi
clinic
trial
treatment
solid
tumor
malign
advanc
stage
nonsmal
cell
lung
cancer
avail
evid
reveal
suffici
robust
therapeut
respons
merit
clinic
develop
furthermor
treatment
null
mice
demonstr
stimul
cytokin
chemokin
product
reduct
tumor
incid
suggest
inhibit
main
molecular
target
action
mani
firstgener
inhibitor
exhibit
potent
action
immun
system
modifi
neoplast
cell
growth
yet
subsequ
found
exhibit
nonselect
activ
independ
action
inhibit
interest
therapeut
potenti
inhibit
treatment
metabol
disord
follow
observ
amid
potent
glucosedepend
stimul
insulin
secret
yet
nativ
amid
exhibit
short
circul
halflif
continu
infus
requir
optim
control
glycemia
mentlein
et
al
identifi
enzym
respons
hydrolysi
incretin
hormon
gip
vitro
find
subsequ
extend
rat
kieffer
et
al
furthermor
rapid
ntermin
cleavag
gip
purifi
rat
serum
substanti
reduc
coincub
inhibitor
diprotin
diminish
presenc
serum
fisher
rat
infus
gip
nh
rat
result
substanti
less
ntermin
cleavag
peptid
illustr
critic
role
incretin
inactiv
vivo
simultan
deacon
et
al
demonstr
cleavag
amid
amid
human
plasma
vitro
action
sensit
inhibitor
diprotin
find
consist
report
pauli
et
al
analyz
degrad
gip
human
serum
vitro
furthermor
circul
level
intact
cleav
isoform
lower
fast
state
rose
meal
ingest
human
subject
subcutan
iv
administr
nativ
normal
diabet
human
subject
led
rapid
degrad
intact
amid
accumul
metabolit
amid
collect
find
highlight
role
key
determin
enzymat
cleavag
inactiv
vitro
vivo
henc
major
physiolog
substrat
complementari
evid
support
essenti
role
control
incretin
degrad
glucos
homeostasi
deriv
studi
rodent
administr
inhibitor
anim
human
inhibitor
valin
pyrrolidid
prevent
degrad
potenti
insulinotrop
glucoregulatori
action
exogen
infus
anesthet
pig
treatment
rat
ilethiazolidid
inhibit
activ
improv
oral
glucos
toler
enhanc
insulin
respons
glucos
find
consist
potenti
endogen
gip
activ
vivo
notabl
inhibit
improv
glycemia
lean
insulinsensit
rat
also
obes
zucker
rat
mark
glucos
intoler
demonstr
inhibit
activ
produc
glucoregulatori
action
experiment
model
dysglycemia
similarli
acut
administr
select
inhibitor
lean
obes
insulinresist
zucker
rat
improv
oral
glucos
toler
augment
increas
plasma
insulin
level
associ
increas
plasma
level
intact
chang
gastric
empti
collect
relat
studi
provid
proof
concept
glucoregulatori
action
inhibitor
insight
metabol
consequ
reduc
absent
activ
came
anim
model
inactiv
mutat
fischer
rat
charl
river
japan
germani
respect
exhibit
loss
activ
due
substitut
near
activ
site
result
degrad
immatur
protein
endoplasm
reticulum
japanes
rat
exhibit
enhanc
glucos
toler
increas
level
circul
enhanc
insulin
secret
basal
condit
rat
demonstr
reduct
bodi
weight
associ
decreas
food
water
intak
ducrj
exhibit
favor
metabol
phenotyp
includ
improv
oral
glucos
toler
increas
insulin
secret
higher
level
intact
plasma
notabl
inhibitor
valinepyrrolidid
modifi
glucos
toler
rat
improv
glucos
toler
control
rat
rat
also
exhibit
resist
highfat
dietinduc
obes
improv
insulin
sensit
resist
streptozotocininduc
hyperglycemia
gener
phenotyp
character
mice
provid
complementari
evid
physiolog
import
glucos
homeostasi
mice
display
increas
circul
level
gip
respons
oral
glucos
challeng
enhanc
glucosestimul
insulin
secret
improv
oral
glucos
toler
consist
data
rat
mice
also
exhibit
resist
dietinduc
obes
reduc
stzinduc
destruct
studi
use
inhibitor
wildtyp
anim
character
rat
mice
mutat
provid
import
valid
glucoregulatori
target
howev
sever
caveat
qualifi
interpret
data
experi
first
initi
gener
inhibitor
complet
select
rais
possibl
action
ascrib
use
agent
vivo
may
reflect
offtarget
activ
second
rat
mice
repres
model
select
inactiv
defici
catalyt
subunit
rather
anim
exhibit
reduc
express
rat
complet
genet
elimin
mice
entir
protein
henc
attribut
mechan
respons
favor
metabol
phenotyp
anim
complic
potenti
action
ensu
loss
action
aris
independ
catalyt
activ
understand
mechan
inhibitor
exert
divers
metabol
action
requir
assess
select
agent
rigor
evalu
evid
link
chang
level
molecular
form
candid
substrat
action
eman
administr
inhibitor
vivo
outlin
tabl
discuss
herein
larg
number
peptid
cleav
vitro
mani
peptid
also
cleav
vivo
furthermor
inhibitor
modifi
rel
level
intact
vs
cleav
substrat
figur
may
exhibit
vari
affin
structur
relat
receptor
figur
complic
assign
mechanist
role
key
peptid
substrat
transduc
action
aris
inhibit
follow
section
describ
experi
support
import
inhibitor
select
critic
evalu
evid
link
chang
level
key
substrat
metabolit
metabol
glucoregulatori
activ
ascrib
inhibit
wherev
possibl
highlight
data
gener
use
select
antagonist
mous
genet
link
presenc
absenc
peptid
action
therapeut
action
ascrib
inhibitor
discoveri
member
famili
proteas
exhibit
postprolin
cleavag
includ
fap
prompt
scientist
reevalu
select
inhibitor
critic
import
glucoregulatori
target
inhibitor
exemplifi
studi
rat
treat
valin
pyrrolidid
demonstr
improv
glucos
toler
compar
reduct
glycem
excurs
control
rat
similarli
valin
pyrrolidid
improv
glucos
toler
wildtyp
mice
fail
lower
glucos
mice
importantli
mice
rat
inactiv
mutat
remain
rel
healthi
exhibit
favor
metabol
profil
henc
rodent
model
provid
key
genet
evid
demonstr
glucoregulatori
target
inhibitor
select
inhibitor
import
enzymat
inactiv
key
substrat
great
interest
fap
also
display
activ
mutat
activ
site
serin
mani
substrat
includ
npi
pyy
interferon
interferoninduc
tcell
chemoattract
also
target
substrat
andor
albeit
much
lower
effici
compar
npi
bnp
sp
pyy
well
gip
may
hydrolyz
fap
howev
overlap
enzymat
specif
chemokin
truncat
observ
rel
import
ubiquit
express
potenti
mediat
toxic
eman
use
nonselect
inhibitor
remain
subject
uncertainti
lanka
et
al
assess
consequ
administ
select
inhibitor
quiescent
cell
prolin
peptidas
rat
dog
wildtyp
mice
select
assess
vitro
respect
recombin
human
enzym
week
treatment
lthreoisoleucyl
thiazolidin
rat
demonstr
lung
histiocytosi
thrombocytopenia
dog
given
treatment
exhibit
acut
central
nervou
toxic
one
two
dose
includ
seizur
tremor
ataxia
observ
lower
dose
bloodi
diarrhea
dog
observ
prolong
therapi
week
treatment
dog
mortal
significantli
increas
addit
toxic
includ
anemia
thrombocytopenia
splenomegali
multiorgan
patholog
observ
allo
isom
alloisoleucyl
thiazolidin
shown
exhibit
greater
potenc
inhibit
potenti
account
observ
preclin
toxic
subsequ
studi
employ
select
inhibitor
produc
thrombocytopenia
splenomegali
lymphadenopathi
lymphocyt
necrosi
mortal
rat
bloodi
diarrhea
emesi
tenesmu
dog
notabl
splenomegali
bone
marrow
myeloid
hyperplasia
excess
mortal
observ
wildtyp
mice
treat
high
dose
select
inhibitor
furthermor
valboropro
select
inhibitor
reduc
cytokin
releas
tcell
prolifer
wherea
inhibitor
effect
assay
vitro
contrast
result
obtain
studi
examin
put
import
potenti
target
vildagliptin
cell
type
vildagliptin
much
potent
inhibitor
rel
inhibit
assess
studi
employ
recombin
human
enzym
vitro
k
valu
nm
respect
vildagliptin
administ
rodent
concentr
mgkgd
dose
produc
plasma
concentr
well
beyond
ki
valu
determin
use
vitro
enzym
assay
inhibit
importantli
tissu
concentr
vildagliptin
exceed
plasma
level
except
muscl
adipos
tissu
brain
howev
specif
detail
drug
level
achiev
differ
tissu
provid
death
observ
vildagliptintr
rat
mice
advers
effect
note
except
modest
increas
red
blood
cell
count
two
highest
dose
even
less
well
understood
observ
inhibitor
vildagliptin
saxagliptin
other
produc
cutan
necrosi
vascul
nonhuman
primat
seem
like
find
reflect
differ
select
intracellular
penetr
metabolit
uniqu
activ
rather
mechanismbas
toxic
howev
molecular
pathophysiolog
underli
preclin
find
remain
poorli
understood
reconcil
differ
preclin
toxic
contrast
conclus
aris
studi
lanka
et
al
burkey
et
al
regard
potenti
import
mediat
offtarget
toxic
specif
enzym
inhibitor
first
studi
assess
structur
distinct
compound
profil
differ
enzymat
assay
vitro
separ
group
anim
vivo
extern
valid
rel
toxic
variou
compound
studi
independ
laboratori
importantli
measur
plasma
even
tissu
level
variou
inhibitor
may
reveal
whether
variou
inhibitor
differenti
pass
across
cell
membran
penetr
intracellular
compart
mani
enzym
may
similarli
access
compound
experiment
differ
observ
may
reflect
differ
variou
compound
access
interact
enzym
resid
key
cellular
subcompart
none
studi
routin
assess
extent
enzym
activ
select
reduc
tissu
within
cell
vivo
challeng
task
given
larg
number
cellular
enzym
relat
enzymat
profil
activ
intriguingli
mutant
mice
serala
point
mutat
catalyt
site
exhibit
normal
enzym
express
reduc
enzymat
activ
normal
embryon
develop
although
mice
born
expect
mendelian
frequenc
exhibit
neonat
mortal
die
shortli
birth
henc
select
genet
ablat
murin
catalyt
activ
scenario
distinct
partial
inhibit
activ
produc
major
organ
toxic
vivo
even
less
known
consequ
select
genet
chemic
reduct
enzym
activ
vivo
seem
clear
toxicolog
data
gener
rodent
may
alway
readili
extrapol
primat
furthermor
import
consid
whether
select
inhibitor
interact
catalyt
site
relev
understand
nonenzymat
action
exampl
bind
extracellular
matrix
protein
includ
fibronectin
collagen
iii
mediat
residu
independ
activ
site
although
action
would
predict
impair
pharmacolog
inhibit
target
proteas
activ
genet
evid
demonstr
action
involv
substrat
cleavag
requir
catalyt
activ
nevertheless
littl
data
demonstr
highli
select
inhibitor
meaning
perturb
action
independ
abil
cleav
peptid
substrat
mice
genet
inactiv
one
incretin
receptor
yield
key
insight
glucoregulatori
mechan
inhibitor
consist
cytoprotect
action
gip
sitagliptin
reduc
apoptosi
wildtyp
mice
treat
streptozotocin
fail
modifi
surviv
gipr
mice
acut
administr
four
structur
distinct
inhibitor
valin
pyrrolidid
improv
oral
glucos
toler
increas
level
plasma
insulin
wildtyp
mice
gipr
mice
contrast
none
inhibitor
lower
glycemia
increas
plasma
level
acut
studi
doubl
incretin
receptor
knockout
dirko
gipr
mice
assess
whether
develop
insulin
resist
glucos
intoler
unmask
import
addit
glucoregulatori
substrat
beyond
gip
flock
et
al
administ
vildagliptin
drink
water
continu
week
highfatf
wildtyp
dirko
mice
vildagliptin
improv
glucos
toler
increas
level
plasma
insulin
wildtyp
mice
improv
glycemia
chang
plasma
insulin
level
detect
vildagliptintr
dirko
mice
demonstr
requir
gip
signal
transduct
chronic
glucoselow
action
inhibitor
contrast
select
chang
express
gene
regul
hepat
lipid
metabol
seen
wildtyp
vildagliptintr
dirko
mice
exact
cellular
site
transduc
glucoregulatori
action
inhibitor
remain
uncertain
although
gip
receptor
islet
logic
candid
level
intact
circul
gip
low
consider
proport
intact
gip
degrad
shortli
secret
gut
endocrin
cell
studi
rodent
use
dose
sitagliptin
suffici
inhibit
intestin
system
activ
implic
local
intestinalneur
mechan
potenti
glucoregulatori
action
inhibitor
howev
exist
potenti
import
similar
circuit
human
difficult
determin
furthermor
select
genet
restor
signal
brain
neuron
suffici
normal
glucos
intoler
mice
henc
elucid
potenti
site
includ
peripher
central
neuron
circuit
islet
cell
contribut
glucoregul
challeng
collect
avail
data
demonstr
gip
necessari
suffici
explain
glucoregulatori
action
inhibitor
mice
howev
addit
substrat
may
involv
mediat
metabol
nonglycem
action
ascrib
inhibit
crossov
placebocontrol
clinic
trial
undertaken
patient
type
diabet
previous
control
diet
exercis
baselin
glycat
hemoglobin
treat
mg
three
time
daili
mg
twice
daili
inhibitor
acetyl
pyrrolidin
nvp
week
administr
nvp
reduc
glucos
profil
decreas
level
fast
postprandi
glucos
unexpectedli
improv
glycem
paramet
associ
reduct
mean
plasma
insulin
level
howev
increas
postprandi
insulin
glucos
ratio
note
consist
improv
function
subsequ
studi
use
vildagliptin
mgd
week
overweight
human
subject
dietcontrol
type
diabet
reveal
inhibit
increas
decreas
plasma
glucagon
level
wherea
plasma
insulin
concentr
remain
unchang
consist
earlier
studi
use
nvp
insulin
glucos
ratio
improv
inhibitortr
subject
studi
first
highlight
correl
improv
glycemia
reduct
plasma
glucagon
diabet
subject
treat
inhibitor
studi
demonstr
sustain
glucos
control
diabet
subject
treat
metformin
either
placebo
vildagliptin
mg
twice
daili
initi
week
follow
addit
openlabel
extens
treatment
vildagliptin
reduc
initi
treatment
period
prevent
deterior
glycem
control
week
sustain
improv
postprandi
glucos
control
fast
glucos
evid
subject
treat
week
signific
differ
insulin
level
bala
et
al
assess
mechan
vildagliptin
improv
glycemia
obes
human
subject
type
diabet
bodi
mass
index
bmi
kgm
baselin
patient
given
singl
dose
vildagliptin
placebo
pm
follow
minut
later
meal
toler
test
vildagliptin
markedli
suppress
plasma
glucagon
level
decreas
endogen
glucos
product
enhanc
insulin
secret
rate
despit
fall
glucos
mechan
sitagliptin
action
studi
overweight
human
subject
type
diabet
treat
sitagliptin
placebo
week
studi
protocol
includ
meal
toler
test
iv
glucos
infus
assess
function
key
find
includ
suppress
endogen
glucos
product
reduc
level
glucagon
level
meal
sitagliptintr
subject
pharmacodynam
effect
chronic
sitagliptin
therapi
administ
alon
combin
metformin
assess
subject
type
diabet
treat
metformin
sitagliptin
alon
combin
week
sitagliptin
either
alon
combin
metformin
significantli
reduc
plasma
glucagon
level
meal
toler
test
associ
drop
endogen
glucos
product
studi
use
inhibitor
treat
human
subject
type
diabet
demonstr
increas
level
intact
gip
often
reduct
total
circul
gip
consist
feedback
inhibit
l
k
cell
secret
respect
auling
et
al
assess
import
endogen
glucoselow
effect
sitagliptin
human
diabet
subject
mean
bmi
kgm
subject
studi
use
oral
iv
glucos
toler
test
acut
administr
sitagliptin
placebo
presenc
absenc
iv
exendin
sitagliptin
increas
fast
level
intact
gip
consist
tonic
feedback
inhibit
secret
activ
exendin
increas
fast
level
activ
presenc
sitagliptin
exendin
partial
revers
glucos
reduct
observ
sitagliptin
treatment
oral
glucos
toler
test
sitagliptin
alon
suppress
level
plasma
glucagon
oral
glucos
toler
test
wherea
coadministr
exendin
led
signific
increas
plasma
glucagon
level
sitagliptintr
subject
find
consist
import
role
augment
signal
inhibitormedi
suppress
glucagon
secret
oral
glucos
toler
partial
complet
revers
sitagliptinmedi
improv
glycem
control
exendin
entir
consist
mous
studi
implic
key
role
gip
glucoselow
action
inhibitor
adipos
tissu
express
sc
viscer
adipos
depot
isol
human
subject
increas
express
associ
impair
glucos
toler
increas
bmi
increas
level
posit
correl
circul
extent
adipocyt
hypertrophi
macrophag
infiltr
insulin
resist
observ
insulinresist
morbidli
obes
patient
dendrit
cell
macrophag
resid
viscer
adipos
depot
also
express
rel
express
cell
type
increas
obes
state
induc
experiment
inflamm
although
well
posit
control
local
concentr
key
bioactiv
substrat
within
adipos
tissu
remain
unclear
whether
adipos
mechanist
contribut
expans
dysfunct
differ
adipos
depot
mice
exhibit
resist
highfat
feedinginduc
obes
associ
increas
express
uncoupl
adrenerg
receptor
brown
adipos
tissu
increas
wholebodi
energi
expenditur
sever
substrat
includ
bnp
oxyntomodulin
shown
stimul
vo
consumpt
andor
thermogenesi
brown
adipos
tissu
howev
mechan
enabl
null
mice
exhibit
resist
dietinduc
obes
identifi
multipl
substrat
pharmacolog
regul
food
intak
includ
npi
pyy
enterostatin
unlik
agonist
inhibitor
suppress
food
intak
gastric
empti
weightneutr
effect
inhibitor
may
simpli
reflect
modest
elev
intact
level
insuffici
control
satieti
andor
chang
level
activ
multipl
anorect
orexigen
peptid
integr
result
reflect
absenc
domin
anorect
signal
express
vascular
endotheli
cell
venou
capillari
bed
enzym
activ
detect
human
fibroblast
reduct
cardiovascular
complic
major
goal
treatment
type
diabet
briefli
review
data
link
inhibit
mechan
action
cardiovascular
system
reader
direct
focus
comprehens
cardiovascular
review
action
detail
null
mice
demonstr
cardioprotect
gene
protein
profil
heart
smaller
remodel
infarct
scar
reduc
mortal
left
anterior
descend
arteri
ligat
similar
cardioprotect
phenotyp
observ
wildtyp
diabet
mice
treat
sitagliptin
direct
intracoronari
administr
sitagliptin
ex
vivo
improv
left
ventricular
develop
pressur
ischemia
reperfus
studi
isol
heart
contrast
heart
mice
wildtyp
mice
treat
two
dose
sitagliptin
hour
exhibit
improv
recoveri
left
ventricular
develop
pressur
henc
inhibit
like
mediat
cardioprotect
indirectli
one
substrat
vivo
despit
abund
preclin
evid
link
inhibit
cardioprotect
mice
rat
cardiac
ischemia
clearli
identifi
like
candid
transduc
cardioprotect
sever
studi
employ
blockad
exendin
identifi
role
signal
cardioprotect
rat
subject
minut
ischemia
hour
reperfus
exhibit
cardioprotect
character
reduc
infarct
size
better
cardiac
perform
reduc
level
bnp
compar
control
rat
find
partial
revers
coadministr
exendin
similarli
administr
exendin
sitagliptintr
spragu
dawley
rat
transient
cardiac
ischemia
increas
cardiomyocyt
apoptosi
revers
sitagliptininduc
improv
ventricular
function
male
mice
subject
experiment
myocardi
infarct
treat
inhibitor
mgkgd
combin
diprotin
mgkg
twice
daili
gcsf
gkgd
demonstr
increas
infarct
size
day
myocardi
infarct
suggest
benefici
effect
observ
mediat
directli
signal
axi
interestingli
regul
maintain
signal
anoth
substrat
gcsf
normal
within
microenviron
bone
marrow
gcsf
induc
suppress
intramarrow
concentr
condit
favor
egress
cell
increas
home
potenti
site
injuri
import
maintain
signal
egress
demonstr
mice
exhibit
select
defect
respons
gcsf
impair
mobil
hematopoiet
progenitor
cell
peripher
blood
consist
find
diabet
mutant
rat
exhibit
defect
mobil
progenitor
cell
respons
treatment
gcsf
induct
circul
stem
cell
extend
diabet
human
subject
plasma
level
level
endotheli
progenitor
cell
isol
flow
cytometri
increas
diabet
subject
week
daili
sitagliptin
administr
although
multipl
preclin
studi
implic
key
cardioprotect
substrat
inhibitor
data
affirm
import
cardioprotect
human
lack
sitagrami
trial
random
patient
acut
myocardi
infarct
placebo
lenograstim
gcsf
gkgd
sitagliptin
mg
differ
ventricular
function
observ
despit
increas
circul
stem
cell
progenitor
day
assess
cardiovascular
safeti
inhibitor
two
outcom
studi
reveal
differ
rate
myocardi
infarct
death
cardiovascular
caus
subject
random
receiv
either
saxagliptin
saxagliptin
assess
vascular
outcom
record
patient
diabet
mellitusthrombolysi
myocardi
infarct
savortimi
alogliptin
examin
cardiovascular
outcom
alogliptin
vs
standard
care
examin
cardiovascular
outcom
trial
experi
reduct
cardiovascular
event
unexpectedli
trial
report
small
signific
increas
rate
hospit
heart
failur
patient
treat
saxagliptin
although
examin
trial
report
statist
signific
increas
hospit
heart
failur
patient
random
alogliptin
small
numer
excess
heart
failur
event
note
alogliptintr
subject
vildagliptin
ventricular
dysfunct
diabet
vividd
trial
conduct
patient
type
diabet
function
heart
failur
class
iiii
new
york
heart
associ
differ
left
ventricular
function
report
year
patient
random
vildagliptin
placebo
increas
left
ventricular
enddiastol
volum
report
patient
random
vildagliptin
therefor
current
clinic
trial
data
patient
establish
cardiovascular
diseas
support
data
preclin
studi
suggest
inhibitor
cardioprotect
inhibitor
reduc
blood
pressur
preclin
studi
although
potenti
mechan
poorli
understood
inhibitor
produc
direct
vasodilatori
effect
isol
preconstrict
aortic
ring
action
requir
circul
substrat
may
transduc
nitric
oxid
cgmp
signal
pathway
prospect
clinic
trial
flowmedi
dilat
fmd
brachial
arteri
measur
patient
type
diabet
treat
sitagliptin
mgd
glucosidas
inhibitor
voglibos
mgd
endotheli
function
significantli
improv
week
treatment
contrast
data
clinic
trial
assess
chang
vascular
function
treatment
inhibitor
reveal
differ
outcom
men
type
diabet
receiv
sitagliptin
mgd
week
exhibit
significantli
attenu
fmd
wherea
treatment
voglibos
mgd
effect
fmd
furthermor
sitagliptin
mgd
alogliptin
mgd
significantli
reduc
fmd
subject
type
diabet
henc
possibl
make
clear
conclus
effect
inhibitor
endotheli
function
diabet
subject
inhibit
also
promot
natriuresi
whether
enhanc
sodium
excret
occur
modul
interact
renal
sodium
hydrogen
exchang
protein
unclear
howev
preclin
studi
demonstr
alogliptin
acut
enhanc
urinari
flow
rate
sodium
secret
wildtyp
mice
henc
although
agonist
potent
induc
natriuresi
mechan
requir
function
mechan
increas
natriuresi
induc
inhibit
known
similarli
although
inhibitor
may
produc
modest
reduct
systol
blood
pressur
clinic
trial
underli
mechan
link
inhibit
reduct
blood
pressur
identifi
express
high
level
brush
border
membran
enterocyt
vascular
lymphat
endotheli
cell
small
intestin
howev
level
much
lower
colon
treatment
mice
hamster
sitagliptin
either
acut
sever
week
reduc
product
triglycerid
rich
lipoprotein
action
mimick
agonist
convers
lipidlow
action
sitagliptin
abrog
wildtyp
mice
treat
exendin
sitagliptintr
mice
multipl
studi
normoglycem
glucoseintoler
diabet
human
subject
demonstr
inhibitor
reduc
postprandi
level
lipoprotein
plasma
triglycerid
circul
free
fatti
acid
furthermor
kinet
studi
healthi
nondiabet
human
subject
studi
pancreat
clamp
condit
demonstr
sitagliptin
reduc
product
rate
lipoprotein
effect
note
product
clearanc
mechan
underli
effect
inhibitor
act
signal
inhibit
intestin
lipoprotein
secret
remain
determin
mice
exhibit
subtl
signific
differ
proport
peripher
lymphocyt
subpopul
spleen
peripher
blood
activ
splenocyt
exhibit
dysregul
stimul
cytokin
product
ex
vivo
signific
decreas
product
increas
furthermor
ig
respons
immun
pokewe
mitogen
lower
mice
togeth
result
suggest
requir
growth
matur
nk
nkt
cell
howev
whether
defect
reflect
select
absenc
catalyt
activ
enzymeindepend
requir
signal
discern
vora
et
al
compar
immun
respons
mice
respons
obtain
ident
immun
challeng
wildtyp
mice
treat
highli
select
inhibitor
antibodi
respons
tcell
antigen
compar
tcell
respons
multipl
antigen
stimuli
ident
mice
vs
mice
vs
wildtyp
mice
treat
select
dpp
inhibitor
enhanc
airway
inflamm
character
increas
cellular
infiltr
enhanc
cytokin
product
observ
mice
challeng
system
aerosol
ovalbumin
whether
find
reflect
global
loss
reduct
catalyt
activ
determin
chemic
inhibit
activ
attenu
featur
encephalomyel
howev
studi
use
nonselect
inhibitor
mechan
link
select
inhibit
immunomodul
remain
incomplet
understood
contrast
sever
studi
administ
highli
select
inhibitor
demonstr
delay
diabet
onset
decreas
insul
increas
number
regulatori
cell
improv
surviv
transplant
islet
nonobes
diabet
mice
wide
studi
model
type
diabet
remark
ex
vivo
treatment
increas
migrat
cell
henc
author
envis
direct
role
inhibitor
control
tcell
migrat
modul
catalyt
activ
vivo
immunomodulatori
action
sitagliptin
also
describ
human
subject
type
diabet
singl
administr
sitagliptin
mg
reduc
express
tolllik
receptor
ikappab
cc
chemokin
receptor
type
decreas
nuclear
factorb
bind
isol
peripher
blood
mononuclear
cell
howev
van
poppel
et
al
found
effect
therapi
vildagliptin
vs
acarbos
plasma
cytokin
level
cytokin
product
ex
vivo
mononuclear
cell
subject
type
diabet
moreov
signific
differ
plasma
level
plasma
cytokin
chemokin
level
proport
major
band
tcell
lymphocyt
subset
includ
number
regulatori
cell
observ
healthi
human
subject
treat
placebo
sitagliptin
mg
daili
day
despit
consider
evid
link
control
retrovir
entri
select
inhibit
activ
hivposit
human
subject
treat
sitagliptin
mg
daili
week
effect
cell
level
plasma
hiv
rna
plasma
chemokin
level
henc
although
multipl
studi
report
modul
inflamm
immun
paramet
reduct
activ
studi
examin
antiinflammatori
action
inhibitor
control
indirect
benefici
consequ
improv
metabol
control
furthermor
effect
mediat
viral
entri
immun
function
independ
catalyt
activ
henc
remain
unclear
whether
partial
select
reduct
enzymat
activ
directli
regul
inflamm
cellular
immun
respons
preclin
clinic
set
treatment
diabet
rodent
inhibitor
reduc
hepat
steatosi
fibrosi
decreas
hepat
inflamm
howev
underli
mechan
identifi
similarli
highfatf
rat
exhibit
reduct
plasma
hepat
triglycerid
lower
level
molecular
marker
proinflammatori
profibrot
cytokin
includ
plasminogen
activ
connect
tissu
growth
factor
although
author
postul
action
mediat
potenti
direct
action
hepatocyt
seem
unlik
hepatocyt
express
canon
inhibitor
also
reduc
liver
enzym
clinic
studi
howev
whether
salutari
action
secondari
independ
improv
glycem
control
unknown
local
brush
border
membran
proxim
tubul
capillari
endothelium
glomeruli
ep
ithelium
bowman
capsul
multipl
studi
rat
mice
demonstr
renoprotect
action
inhibitor
experiment
kidney
injuri
often
associ
reduct
albumin
excret
reduc
express
inflammatori
marker
decreas
oxid
stress
liu
et
al
demonstr
sitagliptin
improv
renal
blood
flow
endotheliumdepend
relax
renal
arteri
decreas
blood
pressur
rat
spontan
hypertens
find
attenu
inhibit
camp
signal
howev
studi
molecular
mechan
inhibit
attenu
renal
injuri
identifi
similarli
sever
clinic
trial
demonstr
reduct
microalbuminuria
subject
type
diabet
treat
inhibitor
howev
littl
mechanist
data
link
reduct
activ
improv
kidney
function
independ
chang
glucos
inflamm
blood
pressur
sever
substrat
includ
gip
pyy
npi
regul
bone
format
resorpt
rodent
mice
exhibit
normal
bone
format
treatment
highfatf
mice
sitagliptin
effect
bone
qualiti
howev
sitagliptin
increas
trabecular
bone
miner
architectur
nevertheless
mechan
key
substrat
regul
bone
turnov
preclin
studi
address
although
diabet
subject
treat
inhibitor
exhibit
modest
reduct
marker
bone
turnov
avail
data
examin
put
chang
bone
densiti
fractur
rate
suffici
firm
conclus
drawn
sinc
regulatori
approv
first
inhibitor
octob
million
patient
type
diabet
treat
inhibitor
surpris
despit
pleiotrop
action
larg
number
potenti
substrat
drug
well
toler
major
advers
event
emerg
recent
descript
increas
rate
hospit
heart
failur
small
subset
saxagliptintr
patient
mandat
addit
investig
identifi
potenti
mechan
link
inhibit
potenti
impair
ventricular
function
individu
despit
hundr
preclin
studi
examin
action
experiment
model
diseas
fundament
understand
key
substrat
transduc
import
action
inhibitor
remain
limit
figur
furthermor
despit
potenti
import
cleavag
target
substrat
mani
put
substrat
cleav
multipl
enzym
disappear
plasma
larg
regul
renal
lesser
extent
hepat
clearanc
henc
identif
domin
role
control
peptid
bioactiv
often
challeng
new
methodolog
use
liquid
chromatographymass
spectrometrybas
technolog
perform
global
peptid
profil
discov
novel
substrat
directli
measur
chang
level
intact
vs
cleav
peptid
respons
genet
delet
catalyt
inhibit
type
analys
expedit
identif
multipl
new
physiolog
substrat
gener
new
hypothes
surround
mechan
action
inhibitor
combin
modern
peptid
profil
technolog
state
art
biochemistri
repres
power
promis
approach
deciph
mechan
key
substrat
transduc
classic
novel
action
inhibitor
anim
human
